Medical Oncology

Vanderbilt

Questions discussed in this category

Would you consider checkpoint inhibitor therapy alone in a patient with metastatic NSCLC with PDL-1 < 1% who is otherwise refusing chemotherapy?

Would nivo + Ipi be appropriate in this situation, especially if high TMB?

4 Answers available

What is the role for "liquid biopsy" for patients with newly diagnosed metastatic NSCLC?

Especially in light of the new Guardant data presented at AACR 2019

2 Answers available

With the FDA approval of third line pembrolizumab for patients with SCLC, how would you select a candidate for pembrolizumab or nivolumab in the third line management of SCLC?

1 Answer available

When do you recommend broader molecular testing for clinical trials in stage IV NSCLC patients who have negative initial molecular testing for FDA-approved targetable mutations?

1 Answer available

For pre-menopausal patients with high-risk ER+ disease, and who desire pregnancy, what is the best time frame to pause endocrine therapy to allow for pregnancy?

High enough risk to justify anthracycline+taxane chemotherapy followed by ovarian suppression + aromatase inhibition.

1 Answer available

Papers discussed in this category

N. Engl. J. Med., 2019 Sep 28

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Related Topics in Medical Oncology